Drugs

, Volume 32, Issue 4, pp 291–312 | Cite as

Oxaprozin

A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy
  • Peter A. Todd
  • Rex N. Brogden
Drug Evaluation

Summary

Synopsis: Oxaprozin1 is a newer non-steroidal anti-inflammatory drug advocated for use in painful rheumatic and inflammatory, conditions. As is the case with some other newer non-steroidal anti-inflammatory drugs, oxaprozin offers the convenience of once-daily administration. Published data suggest that oxaprozin 1200mg once daily is comparable in effectiveness with usual dosages of aspirin, ibuprofen, indomethacin, naproxen, piroxicam and sulindac in the treatment of rheumatoid arthritis and osteoarthritis. More controlled clinical trials in adequate numbers of patients are necessary to evaluate its potential in other rheumatic and inflammatory conditions. Oxaprozin produced fewer gastrointestinal side effects than aspirin, and the short term tolerability of oxaprozin was similar to that of other non-steroidal anti-inflammatory drugs. If further definition of its efficacy and tolerability compared with other non-steroidal anti-inflammatory drugs during long term therapy confirms these initially favourable results, then oxaprozin would appear to offer a useful and convenient alternative in the treatment of painful rheumatic and inflammatory conditions.

Pharmacodynamic Properties: In vitro studies show that oxaprozin, in common with aspirin and other non-steroidal anti-inflammatory drugs, is a potent inhibitor of the cyclo-oxygenase pathway of prostaglandin synthesis. In standard animal models of anti-inflammatory, analgesic and antipyretic activity, oxaprozin is similar in potency to aspirin but less potent than naproxen, piroxicam and indomethacin. Oxaprozin is mildly uricosuric.

The ulcerogenic activity of oxaprozin in animals is less than other standard reference agents such as aspirin, ibuprofen and naproxen when equivalent anti-inflammatory dosages are compared. Unlike most other non-steroidal anti-inflammatory drugs which produce lesions in both the stomach and small intestine of animals, oxaprozin only produces gastric lesions. In man, oxaprozin 1200mg daily produces less faecal blood loss and gastric irritation than aspirin 3900mg daily.

In common with other non-steroidal anti-inflammatory drugs, oxaprozin is a potent inhibitor of platelet aggregation and prolongs bleeding time in man.

In healthy subjects, renal plasma flow is unaffected by the administration of oxaprozin 1200mg daily for 1 week.

Pharmacokinetic Properties: The kinetics of oxaprozin after single or repeated oral administration are characterised by extensive protein binding (⩾ 99.5%), limited volume of distribution (0.15 to 0.25 L/kg), and low rate of systemic clearance (0.0017 to 0.0031 L/h/kg). This leads to a long elimination half-life (about 50 to 60 hours), which makes the drug suitable for once daily administration.

Following single oral doses of oxaprozin 300 to 1200mg, absorption appears complete, although bioavailability studies comparing oral and intravenous administration have not been reported. Peak plasma concentrations are reached in about 2 to 6 hours in most subjects, and absorption is unaffected by food. The plasma concentration of total oxaprozin is non-linearly related to dose, but that of unbound oxaprozin is linearly related. Steady-state plasma concentrations are reached after 4 to 7 days following the repeated oral administration of oxaprozin 600 or 1200mg once daily, when little fluctuation between maximum and minimum plasma concentrations occurs.

There are 2 primary metabolic pathways of oxaprozin excretion in man. Oxaprozin glucuronide is excreted in urine, and 2 hydroxylated metabolites of oxaprozin are excreted mainly as glucuronides in urine and bile. Hydroxylated metabolite excretion is evenly divided between urine and bile. About two-thirds of a radiolabelled dose of oxaprozin is recovered in urine and one-third in faeces.

The sex or age of subjects, and the condition of rheumatoid arthritis, appear to have little influence on the overall disposition of oxaprozin. In patients with renal impairment, plasma concentrations of unbound oxaprozin are increased compared with healthy subjects after a single oral dose of oxaprozin. Further study is required with repeated doses to formulate dosage recommendations. However, an initial dosage not exceeding 600mg once daily has been recommended in azotaemic patients. The free fraction of oxaprozin in plasma is also significantly increased in patients with hepatic impairment or congestive heart failure.

Therapeutic Trials: Most of the studies comparing oxaprozin with other non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis have been of a relatively short duration (4 to 24 weeks). However, from these preliminary data it appears that oxaprozin 1200mg once daily is as effective as aspirin 650 to 812mg 4 times daily in osteoarthritis and as effective as aspirin 925mg 4 times daily in rheumatoid arthritis, with statistically significant results in favour of oxaprozin for some clinical assessments. Oxaprozin was generally better tolerated than aspirin. The efficacy and tolerability of oxaprozin 1200mg once daily were similar to those of naproxen 250mg 3 times daily and piroxicam 20mg once daily in patients with osteoarthritis, and similar to those of ibuprofen 300 to 400mg 4 times daily, sustained release indomethacin 75mg twice daily, naproxen 250mg twice daily and sulindac 200mg twice daily in patients with rheumatoid arthritis.

Single and/or brief reports indicate that oxaprozin may be effective in other rheumatic, inflammatory and painful conditions, such as gouty arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, tendinitis, bursitis and Behçet’s disease. On the basis of one study in patients with postsurgical dental pain, it appears that the analgesic potency of single oral doses of oxaprozin 1200mg and aspirin 650mg are similar but that oxaprozin has a longer duration of action.

Further studies involving greater numbers of patients and extending over longer periods are needed to judge more accurately the relative efficacy and tolerability of oxaprozin compared with commonly used non-steroidal anti-inflammatory drugs in rheumatic and other painful or inflammatory conditions.

Side Effects: Oxaprozin has been well tolerated in most patients to date, and few severe adverse effects have been reported. However, further data are required to determine clearly its side effect profile during longer term therapy, particularly when compared with other frequently used non-steroidal anti-inflammatory drugs. The most frequently reported side effects have been mild gastrointestinal complaints, followed by mild central nervous system effects and rash. A phototoxic reaction has been observed in patients with juvenile rheumatoid arthritis.

From comparative data which are available, oxaprozin appears better tolerated than equivalent dosages of aspirin, in that it causes fewer complaints of gastrointestinal effects and tinnitus. The frequency, severity and nature of side effects appear similar with oxaprozin and usual therapeutic dosages of ibuprofen, naproxen, piroxicam and sulindac.

Dosage: The starting and maintenance dosage of oral oxaprozin is 1200mg once daily, although a starting dosage of 600mg once daily is recommended in azotaemic patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abe S, Moriizumi T, Ohsima T, Higuchi S, Otomo S, et al. Studies on toxicity of oxaprozin (5) tolerance and physical dependence liability in rats. Pharmacometrics 27: 345–352, 1984Google Scholar
  2. Amanuma F, Okuyama S, Orikasa S, Hashimoto S, Yamada C, et al. The analgesic and antipyretic effects of a non-steroidal anti-inflammatory drug, oxaprozin, in experimental animals. Folia Pharmacologica Japonica 83: 345–354, 1984PubMedCrossRefGoogle Scholar
  3. Appelrouth DJ, Chodock AL, Miller JL, Powell WR. A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of rheumatoid arthritis. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 54–58, 1986CrossRefGoogle Scholar
  4. Awouters F, Niemegeers CJE, Lenaerts FM, Janssen PAJ. Delay of castor oil diarrhoea in rats: a new way to evaluate inhibitor of prostaglandin biosynthesis. Journal of Pharmacy and Pharmacology 30: 41–45, 1978PubMedCrossRefGoogle Scholar
  5. Barber JV, Collins RL, Kitridou RC, Lehman DH, Wenger ME, et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of rheumatoid arthritis: a comparison with aspirin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 47–53, 1986CrossRefGoogle Scholar
  6. Bass JC, Athreya BH, Brewer EJ, Goldsmith DP, Hollister JR, et al. A long-acting antiinflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis (JRA). Abstract. Paediatric Research 18: 307, 1984CrossRefGoogle Scholar
  7. Bono RF, Finkel S, Goodman HF, Hanna CB, Rabinowitz SR, et al. Multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis. Clinical Therapeutics 6: 79–85, 1983Google Scholar
  8. Bono RF, Finkel S, Goodman HF, Hanna CB, Rabinowitz SR, et al. Oxaprozin in the treatment of patients with tendinitis and bursitis: comparison with phenylbutazone and placebo. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 90–94, 1986CrossRefGoogle Scholar
  9. Caldwell JR. Summary profile of oxaprozin: comparison with other nonsteroidal antiinflammatory drugs. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 101–107, 1986CrossRefGoogle Scholar
  10. Caldwell JR, Altman RD, Burch FX, Calin A. Treatment of ankylosing spondylitis with oxaprozin: a comparison with indomethacin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 95–100, 1986CrossRefGoogle Scholar
  11. Carlson RP, Chang J, Lewis AJ, Gilman SC. Immunopharmacological properties of oxaprozin (Oxapro®; 4,5-diphenyl-2-oxazolepropionic acid). Abstract no. 3412. Federation Proceedings 42: 875, 1983Google Scholar
  12. Chiang ST, Knowles JA, Hubsher JA, Ruelius HW, Walker BR. Effects of food on oxaprozin bioavailability. Journal of Clinical Pharmacology 24: 381–385, 1984aPubMedGoogle Scholar
  13. Chiang ST, Lasseter KC, Fluck ER, Janssen FW, Leclavathi D, et al. Oxaprozin dose proportionality. Journal of Clinical Pharmacology 24: 515–522, 1984bPubMedGoogle Scholar
  14. Chiang ST, Morrison G, Knowles JA, Ruelius HW, Walker BR. Oxaprozin disposition in renal disease. Clinical Pharmacology and Therapeutics 31: 509–515, 1982PubMedCrossRefGoogle Scholar
  15. Dahl SL, Ward JR. Efficacy and tolerability of oxaprozin in the elderly. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 40–46, 1986CrossRefGoogle Scholar
  16. Davis LJ, Kayser SR, Hubsher J, Williams RL. Effect of oxaprozin on the steady-state anticoagulant activity of warfarin. Clinical Pharmacy 3: 295–297, 1984PubMedGoogle Scholar
  17. Editorial. Duraprox (oxaprozin) Wyeth. In World Pharmaceutical Introductions, pp. PR.28–PR.30, IMS World Publications, London, 1983Google Scholar
  18. Fawthrop FW, Mellor D, Highton J, Palmer DG. Experimental synergism between oxaprozin and diflunisal. Proceedings of the University of Otago Medical School 63: 15, 1985Google Scholar
  19. Ferreira SH, Moncada S, Vane JR. Prostaglandins and signs and symptoms of inflammation. In Robinson & Vane (Eds) Prostaglandin synthetase inhibitors, pp. 175–187, Raven Press, New York, 1974Google Scholar
  20. Ginsberg F, Famaey JP. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. Current Medical Research and Opinion 8: 689–695, 1984PubMedCrossRefGoogle Scholar
  21. Goldfarb S, Walker BR, Agus ZS. Uricosuric and hypouricemic effects of oxaprozin — a non-steroidal anti-inflammatory agent. Abstract. Kidney International 25: 300, 1984Google Scholar
  22. Goldfarb S, Walker BR, Agus ZS. The uricosuric effect of oxaprozin in humans. Journal of Clinical Pharmacology 25: 144–148, 1985PubMedGoogle Scholar
  23. Goto J, Muramatsu M, Hosoda K, Otomo S, Aihara H. The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation. Folia Pharmacologica Japonica 83: 395–400, 1984PubMedCrossRefGoogle Scholar
  24. Greenberg A, Mitnick PD, DeOreo P, Weiner B, Walker B, et al. Differing renal effects of two non-steroidal anti-inflammatory agents (NSAID) in man. Abstract. Clinical Research 28: 237A, 1980Google Scholar
  25. Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, et al. Oxaprozin pharmacokinetics in the elderly. British Journal of Clinical Pharmacology 19: 373–378, 1985PubMedCrossRefGoogle Scholar
  26. Greenblatt DJ, Scavone JM. Pharmacokinetics of oxaprozin and other nonsteroidal anti-inflammatory agents. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 18–26, 1986CrossRefGoogle Scholar
  27. Higuchi S, Osada Y, Shioiri Y, Nakaike S, Muramatsu M, et al. Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models. Folia Pharmacologica Japonica 83: 383–394, 1984PubMedCrossRefGoogle Scholar
  28. Homon CA, Fluck ER, Janssen FW, Ruelius HW. Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent. Agents and Actions 12: 211–215, 1982PubMedCrossRefGoogle Scholar
  29. Hubsher JA, Walker BR. Oxaprozin once daily and ibuprofen qid in the treatment of rheumatoid arthritis: a multicenter study. Abstract no. A45. Clinical Pharmacology and Therapeutics 33: 267, 1983Google Scholar
  30. Hubsher JA, Ballard IM, Walker BR, Gold JA. A multicentre double-blind comparison of oxaprozin aspirin therapy on rheumatoid arthritis. Journal of International Medical Research 7: 69–76, 1979PubMedGoogle Scholar
  31. Hubsher JA, Bono RF, Finkel S, Goodman HF, Hanna CB, et al. Comparison of the efficacy and safety of oxaprozin (4,5-diphenyl-2-oxazole propionic acid) and phenylbutazone versus placebo in the treatment of patients with acute tendinitis/bursitis. Abstract. Clinical Research 30: 806A, 1982aGoogle Scholar
  32. Hubsher JA, Northington RS, Walker BR. Oxaprozin (WY-21,743) once daily in the treatment of rheumatoid arthritis, a multicentre study. Abstract no. C74. Arthritis and Rheumatism 25 (Suppl.): S117, 1982bCrossRefGoogle Scholar
  33. Hubsher JA, Walker BR, Caldwell JR. Oxaprozin (WY-21,743) once daily and aspirin q.i.d. in the treatment of osteoarthritis: a multicentre study. Abstract. Clinical Research 31: 629A, 1983Google Scholar
  34. Jamar R, Dequeker J. Oxaprozin versus aspirin in rheumatoid arthritis: a double-blind trial. Current Medical Research and Opinion 5: 433–438, 1978PubMedCrossRefGoogle Scholar
  35. Janssen FW, Chiang ST, Walker BR, Ruelius HW. Disposition of oxaprozin in healthy subjects and certain disease states. Current Therapeutic Research 35: 363–376, 1984Google Scholar
  36. Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, et al. Metabolism and kinetics of oxaprozin in normal subjects. Clinical Pharmacology and Therapeutics 27: 352–362, 1980PubMedCrossRefGoogle Scholar
  37. Janssen FW, Kirkman SK, Knowles JA, Ruelius HW. Disposition of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin) in beagle dogs and rhesus monkeys. Drug Metabolism and Disposition 6: 465–475, 1978PubMedGoogle Scholar
  38. Jusko WJ, Chiang ST. Distribution volume related to body weight and protein binding. Journal of Pharmaceutical Sciences 71: 469–470, 1982PubMedCrossRefGoogle Scholar
  39. Kahn SB, Hubsher JA. Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding. Journal of Clinical Pharmacology 23: 139–146, 1983PubMedGoogle Scholar
  40. Kolodny AL, Klipper AR, Harris BK, Howard FM, Kahn CB, et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of osteoarthritis: a comparison with aspirin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 72–79, 1986CrossRefGoogle Scholar
  41. Lanza FL, Hubsher JA, Walker BR. Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa. Journal of Clinical Pharmacology 21: 157–161, 1981PubMedGoogle Scholar
  42. Lasseter KC, Chiang ST, Rogers SL, Walker BR. Pharmacokinetics of oxaprozin in patients with hepatic impairment. Abstract. Clinical Research 33: 284A, 1985Google Scholar
  43. Lewis AJ. The pharmacologic profile of oxaprozin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 11–17, 1986CrossRefGoogle Scholar
  44. Lewis AJ, Carlson RP, Chang J, Gilman SC, Nielsen S, et al. The pharmacological profile of oxaprozin, an antiinflammatory and analgesic agent with low gastrointestinal toxicity. Current Therapeutic Research 34: 777–794, 1983Google Scholar
  45. Lewis AJ, Janssen FW, Bonney SL, Ruelius HW, Hubsher JA, et al. Oxaprozin. In Anti-rheumatic and Anti-inflammatory Drugs, Vol. II, CRC Press, 1986Google Scholar
  46. Lewis AJ, Parker J, DiLuigi J, Datko LJ, Carlson RP. Immunomodulation of delayed hypersensitivity to methylated bovine serum albumin (MBSA) in mice using subliminal and normal sensitization procedures. Journal of Immunopharmacology 3: 289–307, 1981–82PubMedCrossRefGoogle Scholar
  47. Lopes Vaz A. Ensaio comparativo duplamente cega com oxa prozin vs indometacina ≪ retard ≫ na artrite reumatóide. Rheumatologia Multidisciplinar (Suppl): 46–52, 1983Google Scholar
  48. Lussier A, LeBel E, Tétreault L. Gastrointestinal blood loss of oxaprozin and aspirin with placebo control. Journal of Clinical Pharmacology 22: 173–178, 1982PubMedGoogle Scholar
  49. McHugh SL, Kirkman SK, Knowles JA. Macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma. Journal of Pharmaceutical Sciences 69: 794–796, 1980PubMedCrossRefGoogle Scholar
  50. Matlis R, Greenblatt DJ. Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. Journal of Chromatography 310: 445–449, 1984PubMedCrossRefGoogle Scholar
  51. Mease PJ, Willkens RF. Treatment of acute gout with oxaprozin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 86–89, 1986CrossRefGoogle Scholar
  52. Mitnick PD, Greenberg A, DeOreo PB, Weiner BM, Coffman TM, et al. Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. Clinical Pharmacology and Therapeutics 28: 680–689, 1980PubMedCrossRefGoogle Scholar
  53. Morrison G, DiPonzio M, Rogers SL, Audet P, Walker BR. The steady-state pharmacokinetics of oxaprozin in patients undergoing hemodialysis. Abstract. Clinical Research 33: 286A, 1985Google Scholar
  54. Palmer DG, Highton J, MacKinnon MJ, Myers DB. Non-steroidal anti-inflammatory drugs in combination. Experimental observations. Clinical and Experimental Rheumatology 3: 111–116, 1985PubMedGoogle Scholar
  55. Pediatric Rheumatology Collaborative Study Group. A once-daily antiinflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis. Journal of Rheumatology 12: 384–386, 1985Google Scholar
  56. Poiley JE, Spindler JS, Clarke JP, Brame CL. Nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis: a comparison of oxaprozin and Ibuprofen. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 59–65, 1986CrossRefGoogle Scholar
  57. Powell WR, Bonney SL, Hubsher JA, Walker BR. Oxaprozin (O) and Piroxicam (P) once daily in the treatment of osteoarthritis. Abstract no. C26. Clinical Pharmacology and Therapeutics 37: 222, 1985Google Scholar
  58. Powell WR, Miller JL, Sheldon WB. Once-daily oxaprozin and piroxicam compared in osteoarthritis. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 80–85, 1986CrossRefGoogle Scholar
  59. Rainsford KD. Comparison of the gastric ulcerogenic activity of new non-steroid anti-inflammatory drugs in stressed rats. British Journal Pharmacology 73: 226P–227P, 1981Google Scholar
  60. Reynolds WJ, Shaar SF, Buik A, Lancee WJ. Oxaprozin: a once-daily regimen in rheumatoid arthritis. Journal of Rheumatology 6: 345–350, 1979PubMedGoogle Scholar
  61. Rosenthale ME, Begany AJ, Dervinis A, Malis JL, Shriver DA, et al. Anti-inflammatory properties of 4,5-diphenyl-2-oxazolepropionic acid. Agents and Actions 4: 151–159, 1974PubMedCrossRefGoogle Scholar
  62. Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS. Interaction of oxaprozin with acetaminophen, Cimetidine, and ranitidine. Abstract. Journal of Clinical Pharmacology 25: 461, 1985Google Scholar
  63. Schorn D. A comparison between oxaprozin and naproxen in rheumatoid arthritis. South African Medical Journal 60: 768, 1981PubMedGoogle Scholar
  64. Shriver DA, Dove PA, White CB, Sandor A, Rosenthale ME. A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazic in arthritic and Lewis normal rats. Toxicology and Applied Pharmacology 42: 75–83, 1977PubMedCrossRefGoogle Scholar
  65. Shriver DA, White CB, Sandor A, Rosenthale ME. A profile of the rat gastrointestinal toxicity of drugs used to treat inflammatory diseases. Toxicology and Applied Pharmacology 32: 73–83, 1975CrossRefGoogle Scholar
  66. Sofia RD, Danielsen L, Vassar HB. Comparative effects of antiarthritic and other pharmacological agents in the 18-hour arthritis and carrageenan edema tests in rats. Pharmacological Research Communications 11: 179–193, 1979PubMedCrossRefGoogle Scholar
  67. Suwa T, Kohno Y, Urano H, Miragawa T, Kyogoku K. Metabolic fate of oxaprozin (2) distribution of 14C-oxaprozin. Pharmacometrics 27: 141–146, 1984aGoogle Scholar
  68. Suwa T, Urano H, Kohno Y, Minagawa T, Kyogoku K. Metabolic fate of oxaprozin (4) foeto-placental transfer, excretion into milk and repeated administration of 14C-oxaprozin in rats. Pharmacometrics 27: 157–163, 1984bGoogle Scholar
  69. Takeuchi A, Mori M, Hashimoto A, Chihara T. Efficacy of oxaprozin in the treatment of articular symptoms of Behçet’s disease. Clinical Rheumatology 3: 397–399, 1984PubMedCrossRefGoogle Scholar
  70. Tsuchida K, Higuchi S, Kurachi M, Arai I, Isobe Y, et al. General pharmacology of oxaprozin (2) effects on the cardiovascular and autonomic nervous systems. Pharmacometrics 27: 329–344, 1984Google Scholar
  71. Vane JR. Mode of action of aspirin and similar compounds. In Robinson & Vane (Eds) Prostaglandin synthetase inhibitors, pp. 155–163, Raven Press, New York, 1974Google Scholar
  72. Verburg-Ochs B, Ochs HR, Greenblatt DJ. Oxaprozin kinetics in congestive heart failure. Clinical Pharmacology and Therapeutics 37: 235, 1985Google Scholar
  73. Vreede PD, Harper FE, Sheldon WB. Use of oxaprozin in the treatment of aspirin failures in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 66–71, 1986CrossRefGoogle Scholar
  74. Walker B, Bonney SL. Perfil terapêutico do oxaprozin. Rheumatologia Multidisciplinar (Suppl.): 75–78, 1983Google Scholar
  75. Whitehouse MW, Kipper I, Klinenberg JR. Biochemical properties of anti-inflammatory drugs — XII. Biochemical Pharmacology 20: 3309–3320, 1971PubMedCrossRefGoogle Scholar
  76. Winter Jr L, Post A. Double-blind comparison of single oral doses of oxaprozin, aspirin, and placebo for relief of post-operative oral surgery pain. Journal of International Medical Research 11: 308–314, 1983PubMedGoogle Scholar
  77. Zimmerman HJ. Hepatic effects of oxaprozin. Seminars in Arthritis and Rheumatism 15(Suppl. 2): 35–39, 1986CrossRefGoogle Scholar
  78. Zuccollo R, Mackinnon MJ, Fraser KM, Hall SM, Palmer DG. Oxaprozin and sulindac in rheumatoid arthritis: a double-blind comparative study. Current Medical Research and Opinion 8: 302–309, 1983PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Peter A. Todd
    • 1
  • Rex N. Brogden
    • 1
  1. 1.ADIS Drug Information ServicesMairangi Bay, Auckland 10New Zealand

Personalised recommendations